Blue-blocking Glasses for Sleep Disorders in Child and Adolescent Psychiatry
Key facts
- Where
- Haugesund and Tromsø, NorwaySee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 18 years old?
Source: NCT07433491, who can take part
Where in Norway
- BUP HaugesundHaugesund, NorwayContact: Sigrund Drivenes, MScTaking people
- BUPA Tromsø, The University Hospital of North NorwayTromsø, NorwayContact: Christian Eckhoff, MD, PhDNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Helse Fonna
- Trial code
- NCT07433491
- Record updated
- 18 September 2026
- Original description
Sleep problems and regulation difficulties are frequent in the child and adolescent psychiatry population. Insomnia and delayed sleep-wake phase disorders (DSPWD) are highly prevalent, and risk factors for developing more severe illness courses and chronic disorders. Pharmacological treatments of sleep disorders dominate even for the youngest patients but are unsupported by long-term data on outcome and side effects. The majority of non-pharmacological treatment options are composite and resource demanding. The investigators will examine the effects and feasibility of the isolated intervention of evening/night use of blue-blocking glasses/real darkness as adjunctive treatment for insomnia and delayed sleep phase disorder in inpatient and outpatient settings for children and adolecents.Read full original descriptionShow less
Blue-blocking Glasses for Treating Evening Activation and Sleep Disorders in Child and Adolescent Psychiatry - a Pilot Trans-diagnostic Randomized Controlled Trial.
Sleep problems and regulation difficulties are frequent in the child and adolescent psychiatry population. Insomnia and delayed sleep-wake phase disorders (DSPWD) are highly prevalent, and risk factors for developing more severe illness courses and chronic disorders. Pharmacological treatments of sleep disorders dominate even for the youngest patients but are unsupported by long-term data on outcome and side effects. The majority of non-pharmacological treatment options are composite and resource demanding. The investigators will examine the effects and feasibility of the isolated intervention of evening/night use of blue-blocking glasses/real darkness as adjunctive treatment for insomnia and delayed sleep phase disorder in inpatient and outpatient settings for children and adolecents.
Inclusion: Age 12-18 years, receiving health-care from child and adolescent mental health services at UPA University Hospital of North Norway, Tromsø or BUP Haugesund Hospital, Haugesund; Current Insomnia or DSPD comorbid to one or several pychiatric symptom presentations or diagnoses; Able and willing to provide written informed consent; Participants aged 12-15,9 years also need consent from both parents/carers; Able to comply with protocol; Able to discontinue melatonin or BB-glasses if currently used, with at least 3 days washout period.
Exclusion: Consent from both partents/carers unlikely (participants age 12-15,9 years); Not able to comply with protocol for a required minimum of one night; Blindness or severely reduced translucency of both eyes; Known malformation or damage of optical tract blindness; Use of melatonin all formulas that cannot be paused; High risk for suicide or self-harm.